Overview
Sunshine Holdings is a diversified Sri Lankan group spanning healthcare, consumer goods and agribusiness. The latest September quarter combined strong sales growth with a sharp rise in group profit, although the operating margin was below the comparable prior-year quarter. The valuation band begins at Fairly valued, but the assessment ends bearish because the price carries a substantial sector and own-history premium while dividend payments exceed trailing earnings.
Price performance
At LKR 31.30 on 11 November 2026, SUN had fallen 7.7% over one year against a 3.9% decline in the ASPI, while its 11.4% one-month gain exceeded the index's 9.7%. The share stood 35.0% of the way from its 52-week low to high, so it remained closer to the low than the high despite the recent rebound.
The record since November 2023 shows two falls of 15% or more, the deepest 31.4%, which has not yet recovered. Median daily turnover was LKR 7.2 million; a LKR 1 million order is about 14% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
The P/E is 20.2 times, meaning the market price pays LKR 20.20 for each LKR 1 of trailing profit, while the 3.01 times P/B pays LKR 3.01 for each LKR 1 of net assets. The P/B sits above 90% of sector peers, and the P/E and P/B are more expensive than at all 14 recorded year-ends. This is a high price relative to both peers and Sunshine's own record.
The 7.3% dividend yield is the highest among the 17 sector peers with yield data, but the payout rose from LKR 0.98 in FY2025 to LKR 1.80 in FY2026. A buyer at this price is relying materially on the latest quarter: it supplied 41.9% of trailing EPS, and the P/E would be 22.6 times had that quarter earned its year-ago net margin.
News and sentiment
Coverage was unusually heavy, with 11 articles in 30 days against Sunshine's normal monthly baseline of 4.2. Of 17 material articles over 90 days, 11 were positive, three negative and three neutral.
Reports on 16 October described a more than USD 20 million Zydus joint venture for a Horana pharmaceutical plant, with commercial operations expected in 2028. The announced earnings contribution is not disclosed. Sunshine Healthcare's LKR 410.8 million purchase of a 21.92% Doc990 stake, reported on 19 October, is small against FY2026 revenue of LKR 65.9 billion but expands the healthcare portfolio into digital services.
Financials
September-quarter revenue rose 32.0% year-on-year to LKR 21.6 billion, while group net profit rose 76.6% to LKR 2.3 billion. Gross margin was 29.1% versus 32.1% a year earlier, operating margin 16.8% versus 17.4%, and net margin 10.8% versus 8.1%. Thus, profit grew faster than sales even though the underlying gross and operating margins narrowed.
September has been Sunshine's strongest quarter for operating margin on average over six complete years on record. Even so, the 16.8% operating margin was among the worst of its seven comparable September quarters, and gross margin was the worst of seven. The LKR 1.3 billion gap between operating and net profit was smaller than the year-ago LKR 1.5 billion drag, helping net profit rise faster than operating profit.
The latest audited year ended March 2026, when revenue grew 11.2% but net profit fell 14.8% and return on equity was 15.3%. Group profit also includes material minority interests: 39.4% of FY2026 profit belonged to minority shareholders rather than the ordinary shares being valued.
Risks
The most immediate financial risk is the dividend burden. Trailing distributions equal 148.4% of earnings and dividend cover is only 0.67 times, so cash distributions are running ahead of the profit available to support them.
FY2026 debt was 47.8% of equity attributable to owners, although interest cover was 12.94 times, meaning operating profit covered the interest bill nearly thirteen times. The current ratio was 1.73 times, or LKR 1.73 of short-term assets for each LKR 1 of bills due within a year, while cash conversion was 0.84 times, indicating operating profit did not fully arrive as operating cash. Healthcare accounts for 56.8% of reported segment revenue, where recent company reporting cited regulated pharmaceutical price cuts; consumer retail, at 28.9% of segment revenue, also operates against an inflation backdrop that constrains household purchasing power.
Outlook
As at 12 November 2026, the next defined company event is the interim filing for the quarter ending 31 December 2026, expected between 4 and 14 February 2027. It will show whether the September profit acceleration persists after a quarter whose operating margin is normally Sunshine's strongest, and will update the effect of healthcare pricing pressure.
The LKR 0.50 first interim dividend went ex on 10 November, so a buyer after that date does not receive it; payment is due on 30 November. The available data cannot yet quantify earnings from the Zydus plant or the Doc990 associate investment.